Costing total hip arthroplasty in a South African state tertiary hospital by Sekeitto, A R & Aden, A A
250       March 2021, Vol. 111, No. 3
RESEARCH
Total hip arthroplasty (THA) has proved to be a life-improving 
procedure since its inception in the 1970s.[1] It is among the most 
cost-effective interventions in medicine in terms of cost per quality-
adjusted life-years gained.[2] According to the 2016 South African 
National Joint Registry Annual Report,[3] 47.6% of all entries from 
December 2012 to December 2015 were primary THAs.[3] In South 
Africa (SA), the ageing population has increased the demand for 
arthroplasty services in keeping with global trends referred to as 
an impending epidemic.[1,4-7] The public sector, which provides 
healthcare to 84% of the SA population, is under the spotlight with 
regard to arthroplasty waiting lists.[8] In light of the current budgetary 
constraints, there is a substantial economic burden associated with 
arthroplasty.[1,5,9]
Arthroplasty costs vary according to frequency of the procedure, 
varied inpatient services, availability of medical supplies, other 
treatment modalities utilised, and patient diversity.[10] Meyers et al.[10] 
found that the major cost drivers were the prosthesis, anaesthesia/
operating room and nursing/hospital costs. They concluded that 
standardisation alongside development of critical pathways will 
reduce case-to-case variation and result in a substantial decrease in 
costs. Rana and William[6] showed that the above three factors made 
up 66% of total cost. The strongest correlation with total cost was 
hospital length of stay (LoS). However, they felt that this cost cannot 
be reduced further without compromising the quality of care.
Locally, the Gauteng Department of Health has developed initiatives 
to address surgical backlogs, particularly arthroplasty, by introducing 
a week-long blitz where arthroplasty patients are operated on 
during dedicated periods.[11,12] This week-long blitz, termed Move 
and Walk week, was launched at Helen Joseph Hospital (HJH) in 
October 2015, ushering in the first documented implementation of 
standardised procedures for arthroplasty in the public sector. This 
initiative, supported by development of a critical pathway through 
a multidisciplinary approach for perioperative management of these 
patients, entailed doing 25 - 30 operations in a week.[13]
Clinicians are generally not familiar with costs of patient care. 
An SA study showed that providing information to clinicians on 
laboratory test costs led to a significant drop in numbers of tests 
requested and associated cost, saving as much as 36% per day.[14] 
Treating clinical teams’ awareness of cost drivers in THA has been 
shown to improve cost-containment measures.[15]
Objectives
To determine the cost of an uncomplicated primary THA in a public 
hospital, to identify its cost factors, and to make recommendations 
on cost optimisation.
Methods
We conducted a cross-sectional study at HJH. The study population 
consisted of patients aged >18 years who underwent total primary 
hip arthroplasty during the Move and Walk weeks from October 
2015 to March 2017. Patients who were operated on outside the Move 
and Walk weeks and those who had revision THA were excluded. 
The study was approved by the Human Research Ethics Committee 
of the University of the Witwatersrand (ref. no. M161147). Data 
were collected from hospital records and the Move and Walk weeks 
financial records.
Costs associated with THA were divided into six cost centres: 
inpatient admission, theatre and anaesthesia, ambulatory, prosthesis, 
physiotherapy and blood bank. These centres were derived from the 
financial audit of the Move and Walk weeks at HJH. The inpatient 
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cost was calculated from the daily admission rate multiplied by the 
number of admission days. The laboratory cost was calculated from 
the National Health Laboratory Service invoice of each patient. The 
prosthesis cost was determined from the invoice submitted by the 
respective implant companies. The blood bank service cost, which 
comprised type and screen fee, after-hours levy and cost of blood 
products issued, was derived from the invoice incurred by the patient. 
The theatre and anaesthesia cost, which covered the expenditure 
incurred during the perioperative period in theatre, was provided by 
the HJH finance department.
Data were analysed using descriptive statistics for the demographic 
data and cost variables. The cost of each cost centre was evaluated in 
ZAR. The statistical analysis of continuous variables was presented 
using means and standard deviations (SDs). Since the total cost is 
the sum of all the cost centres, the quantiles were used to classify 
cost variables into categories of high, medium and low for all cost 
centres. Quantiles represent a statistical categorisation of continuous 
variables based on the representation from the sample. These 
categories were then used to evaluate whether there were significant 
differences between the patients within these cost centres. Analysis of 
variance (ANOVA) was used to test whether there was any significant 
difference between the means of more than two independent 
groups. The results of the F-statistics and their corresponding 95% 
significance levels were displayed in tables. If a significant difference 
was found, the least significant difference (LSD), calculated from 
the results of the ANOVA, was used to test, at an overall 5% level of 
significance. The LSD tests which pairs of categories are significantly 
different from each other, when there are more than two categories.
Results
Fifty-five patients met the inclusion criteria. There were 14 males 
(25.6%) and 41 females (74.6%), with an age range of 42 - 82 years 
(mean (SD) 62.9 (10.7) years). The side of the procedure was left in 
20 cases (36.4%), and right in 35 (63.6%).
The mean (SD) LoS was 7.5 (2.4) days, with preoperative and 
postoperative LoS of 2.8 (1.8) days and 4.8 (2.0) days, respectively. 
The mean (SD) inpatient cost was ZAR13 721.24 (4 340.72), with 
a minimum and maximum of ZAR7 124.00 and ZAR28 496.00, 
respectively (Table 1).
The mean (SD) prosthesis cost was ZAR40 305.16 (9 501.11), with 
a minimum and maximum of ZAR30 000.00 and ZAR72 761.22, 
respectively. The variation in cost is explained by certain companies 
having predetermined set pricing agreements with the hospital while 
others did not. The theatre and anaesthesia cost was a predetermined 
amount of ZAR17 243.00, and it remained unchanged during the 
study period. No statistical analysis was performed on this cost 
centre. The ambulatory cost was inclusive of costs of X-rays, 
electrocardiograms (ECGs), consulting, laboratory investigations 
and intravenous fluids. The HJH finance department calculated a 
fixed amount of ZAR1 141.00 to cover the first three items. The mean 
(SD) laboratory cost was ZAR1 391.54 (248.89), with a minimum 
and maximum of ZAR1 156.60 and ZAR2 837.33, respectively. The 
physiotherapy cost was billed per session at ZAR105.00. Patients 
received a single session preoperatively, and two sessions per day from 
day 1 postoperatively until discharge. Table 1 illustrates that the mean 
(SD) cost was ZAR798.00 (9 269.30) with a minimum and maximum 
of ZAR420.00 and ZAR1 890.00, respectively. The blood bank mean 
(SD) cost was ZAR726.32 (1 164.85), with a minimum and maximum 
of ZAR320.31 and ZAR7 396.35, respectively (Table 1).
The total cost for primary THA was calculated from the sum 
of all the cost centres. The mean (SD) cost was ZAR74 185.25 
(10 792.83), with a minimum and maximum of ZAR60 414.04 
and ZAR110 598.62, respectively (Table 1). Fig. 1 illustrates the 
percentage contribution of each cost centre to the total cost.
Table 2 shows the cost centres in quantiles. Quantiles were used 
to classify all cost centres into high, medium and low categories, 
as shown in Table 3. These categories were then used to evaluate 
whether there were significant differences between patients.
ANOVA was used to test whether there was any significant 
difference between the three levels. The results of the F-statistics 
and their corresponding 95% significance levels are displayed in 
Table 4. Type I SS is the sum of square associated with rejecting 
Table 1. Descriptive statistics of the respective cost centres
Cost (ZAR)
Cost centre Mean (SD) Minimum Maximum 
Prosthesis 40 305.16 (9 501.11) 30 000.00 72 761.22 
Inpatient admission 13 721.24 (4 340.72) 7 124.00 28 496.00 
Ambulatory 1 391.54 (248.89) 1 156.60 2 837.33 
Theatre and anaesthesia 17 243.00 (-) 17 243.00 17 243.00 
Physiotherapy 798.00 (269.30) 420.00 1 890.00 
Blood bank 726.32 (1 164.85) 320.31 7 396.35 
Overall total cost 74 185.25 (10 792.83) 60 414.04 110 598.62 






Prosthesis         Inpatient admission  
Ambulatory         Theatre and anaesthesia  
Physiotherapy      Blood bank
Fig. 1. Contribution (%) of the six cost centres to the total cost of primary 
hip arthroplasty.
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a true null hypothesis. The null hypothesis is that there is no 
significant difference between the categories of the cost centres. The 
overall model is significant, and it was found that there were some 
significant differences between the categories of prothesis cost centre, 
inpatient admission cost centre and ambulatory cost centre at a 95% 
significance level (p<0.05).
The LSD (Table 5), calculated from the results of the ANOVA, 
was used to test at an overall 5% level of significance, which 
pairs categories that differ significantly. The inpatient admission, 
prosthesis, ambulatory and physiotherapy cost centres showed 
significant differences between high and low, and between high 
and medium, categories, while there was no significant difference 
between low and medium categories. The blood bank cost centre 
showed a significant difference between high and low categories, 
and no significant differences between the low and medium, and 
high and medium, categories. However, the ambulatory cost centre 
demonstrated no significant differences between the categories.
Discussion
The mean age of the patients was comparable to the reported 
age in the literature, as was mean LoS in hospital, despite the 
preoperative mean (SD) of 2.8 (1.8) days in our study.[16] The latter 
was required because of logistical constraints in the state sector, 
caused by the burden of trauma, to ensure availability of beds for these 
patients. Batsis et al.[17] have shown that LoS is a key determinant of 
resource utilisation,[17] hence the suggestion of proper postoperative 
streamlining of patients to reduce LoS. In fact, outpatient THA in 
appropriately selected patients has shown financial benefits when 
supported by clear perioperative protocols, with no increase in 
readmission or complications.[18-21] However, we are of the opinion 
that the SA public health system and patient population are currently 
not ready for outpatient THA.
The average prosthesis cost was ZAR40 305.20. However, since 
surgeons were allowed to use their preferred implant company, and 
some of the companies had no pre-set pricing with the hospital, this 
cost varied. This programme started before the Gauteng Province 
orthopaedic tender came into effect in 2017. Barber and Healy[22] 
found that the cost of the prosthesis amounted to 24% of the total 
inpatient cost, compared with 53.9% in our study. In the past decade, 
the price of a total hip prosthesis has risen by 212% in the USA, 
and variation of as much as 700% has been reported.[9,16] This trend 
does not follow the usual economies-of-scale principles, according 
to which the cost of the prosthesis should decline with increased 
numbers of procedures[22,23] – hence the need for standardisation 
recommended in many studies.[6,22,23] The theatre and anaesthesia 
cost was a fixed set amount during this study, and was therefore 
excluded from the statistical analysis. The ambulatory cost centre, 
which included investigations such as laboratory investigations, 
imaging and ECGs, as well as intravenous fluids, has already been 
standardised. The physiotherapy cost centre was not shown to be 
statistically significant, and we therefore offer no cost-containment 
recommendation. In the blood bank cost centre, our study showed 
that 25% of the patients (n=14) incurred an after-hours levy. We 
consider that this figure is too high, given the reported increased rate 
of allogenic blood transfusions after THA.[24]
In 2017, the private sector in SA implemented fixed global 
fee products to remunerate participating entities within total 
joint arthroplasty. Professional societies are opposed to this 
Table 2. Quantiles of the cost centres
Cost (ZAR)
Cost centre Maximum Q3 Q1 Minimum
Prosthesis 72 761.20 42 829.80 34 000.00 30 000.00
Inpatient admission 28 496.00 15 104.00 11 328.00 7 124.00
Ambulatory 2 837.33 1 373.96 1 297.14 1 156.60
Physiotherapy 1 890.00 840.00 630.00 420.00
Blood bank 7 396.35 709.01 320.31 320.31
Q = quantile.
Table 3. Categories according to frequency
Cost centre High, n (%) Medium, n (%) Low, n (%)
Prosthesis 14 (25.5) 27 (49.1) 14 (25.5)
Inpatient 14 (25.5) 21 (38.2) 20 (36.4)
Ambulatory 14 (25.5) 27 (49.1) 14 (25.5)
Physiotherapy 17 (30.9) 19 (34.6) 19 (34.6)
Blood bank 14 (25.5) 27 (49.1) 14 (25.5)
Table 4. F-statistics of the cost centres
Cost centre df Type I SS Mean square F-value Pr(>F)
Prosthesis 2 3 887 318 824 1 943 659 412 86.93 0.0001*
Inpatient admission 2 1 232 716 448 616 358 224 27.57 0.0001*
Ambulatory 2 153 004 074 76 502 037 3.42 0.0416*
Physiotherapy 2 5 674 515 2 837 258 0.13 0.8812
Blood bank 2 27 654 007 13 827 004 0.62 0.5434
df = degrees of freedom; Type 1 SS = sum of square associated with rejecting a true null hypothesis.
*Significant at the <0.05 level.
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implementation, as it potentially leads to unethical conduct and a 
power imbalance driven by funders and facilities, and contravenes 
Health Professions Council of South Africa guidelines. The greatest 
risks to patients are underservicing and additional costs due to 
co-payments (Discovery Health, Advisory on global fee arrangement 
participation (press release), 2016 – unpublished).
In our study, the mean total cost of primary THA, which was 
ZAR74 185.25 with a minimum and maximum of ZAR60 414.04 
and ZAR110 598.62, respectively, compares favourably with the cost 
in the private sector. Although our study did not calculate the cost 
of the surgical team and the anaesthetist, this figure is substantially 
lower than the cost in both the bundle-fee model and the fixed-fee 
model of the Discovery Health joint arthroplasty network, which 
were both ZAR133 262.00 in 2018 (Discovery Health, Elective hip 
and knee network agreement, 2017, and Joint arthroplasty agreement, 
2018 – both unpublished). An interesting observation is the cost of 
the prosthesis in the private sector being limited to ZAR35 000.00 
because of strong bargaining with implant companies, which was 
not the established protocol in our hospital. Moreover, the maximum 
physiotherapy cost in our study compares favourably with the private 
physiotherapy cost.
Study limitations
Our study was limited by the small number of patients in comparison 
with other studies. It did not explore the relationship between 
indication for THA and impact on cost, which was shown to be a 
cost factor. We relied on the availability and adequacy of the financial 
data linked to patients undergoing THA, and we excluded the cost of 
chronic medication and overhead facility costs. Most of all, while our 




• Collective bargaining with implant companies to fix prosthesis 
cost.
• Reserving dedicated elective beds for rolling scheduled admissions 
for elective cases.
• Developing postoperative protocols in keeping with studies 
advocating for standardisation.
• Subdividing the theatre and anaesthesia cost centre into variables 
to obtain accurate figures.
• Respecting physicians’ clinical autonomy regarding investigations 
to safeguard patient safety.
• Doing blood typing and screens the day before or on the morning 
of the procedure to avoid incurring an after-hours levy.
• Pro-rata estimation of the cost of the time spent by the surgical 
and anaesthetic teams to obtain comprehensive costing of THA in 
the public sector.
• Costing of all cost-driven procedures within orthopaedics.
Conclusions
The demand for THA in SA is increasing in keeping with the global 
trend. The cost of healthcare services is coming under scrutiny 
owing to constrained budgets in the current financial climate. The 
private sector, however controversial, has been the forerunner in the 




95% CL for LSMean(i) - 
LSMean(j)




High - low 19 974 14 818 - 25 130 0.0001*
High - medium 18 911 14 418 - 23 403 0.0001*
Low - medium –1 063.413968 –5 555.846272 - 3 429 0.6368
Inpatient admission
Category combination
High - low 13 457 6 769.492089 - 20 145 0.0002*
High - medium 9 719.479048 3 097.653853 - 16 341 0.0048*
Low - medium –3 737.728667 –9 734.046412 - 22 58.6 0.2166
Ambulatory
Category combination
High - low 8 107.377857 157.682782 - 16 057 0.0458*
High - medium 6 972.997196 45.991906 - 13 900 0.0486*
Low - medium –1 134.380661 –8 061.385951 - 5 792.6 0.7438
Physiotherapy
Category combination
High - low 11 557 4 989.587194 - 18 124 0.0009*
High - medium 8 858.847678 2 291.626668 - 15 426 0.0092*
Low - medium –2 697.960526 –9 080.152158 - 3 684.2 0.4002
Blood bank
Category combination
High - low 8 941.309286 980.150623 - 16 902 0.0285*
High - medium 4 757.814233 –2 179.17991 - 11 695 0.1746
Low - medium –4 183.495053 –11 120 - 2 753.5 0.2317
CL = confidence limits; LSMean = least squares mean.
*Significant at the <0.05 level.
254       March 2021, Vol. 111, No. 3
RESEARCH
attempt to contain costs, and claims to have had success. Our study 
reviewed the literature and studied a cohort of arthroplasty patients 
in a local setting as well as the prevailing local industry practice. We 
analysed the six cost centres and provide eight recommendations for 
cost-containment measures on THA performed in the public sector.
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